Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary) ; Remdesivir (Primary)
- Indications Cardiovascular disorders; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms DEFEND
- 31 Jan 2025 New trial record